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Summary
Background In north India many pre-school children are underweight, many have intestinal worms, and 2–3% die at 
ages 1·0–6·0 years. We used the state-wide Integrated Child Development Service (ICDS) infrastructure to help to 
assess any eﬀ ects of regular deworming on mortality.
Methods Participants in this cluster-randomised study were children in catchment areas of 8338 ICDS-staﬀ ed village 
child-care centres (under-5 population 1 million) in 72 administrative blocks. Groups of four neighbouring blocks 
were cluster-randomly allocated in Oxford between 6-monthly vitamin A (retinol capsule of 200 000 IU retinyl acetate 
in oil, to be cut and dripped into the child’s mouth every 6 months), albendazole (400 mg tablet every 6 months), both, 
or neither (open control). Analyses of albendazole eﬀ ects are by block (36 vs 36 clusters). The study spanned 5 calendar 
years, with 11 6-monthly mass-treatment days for all children then aged 6–72 months. Annually, one centre per block 
was randomly selected and visited by a study team 1–5 months after any trial deworming to sample faeces (for 
presence of worm eggs, reliably assessed only after mid-study), weigh children, and interview caregivers. Separately, 
all 8338 centres were visited every 6 months to monitor pre-school deaths (100 000 visits, 25 000 deaths at age 
1·0–6·0 years [the primary outcome]). This trial is registered at ClinicalTrials.gov, NCT00222547.
Findings Estimated compliance with 6-monthly albendazole was 86%. Among 2589 versus 2576 children surveyed 
during the second half of the study, nematode egg prevalence was 16% versus 36%, and most infection was light. 
After at least 2 years of treatment, weight at ages 3·0–6·0 years (standardised to age 4·0 years, 50% male) was 
12·72 kg albendazole versus 12·68 kg control (diﬀ erence 0·04 kg, 95% CI –0·14 to 0·21, p=0·66). Comparing the 
36 albendazole-allocated versus 36 control blocks in analyses of the primary outcome, deaths per child-care centre at 
ages 1·0–6·0 years during the 5-year study were 3·00 (SE 0·07) albendazole versus 3·16 (SE 0·09) control, diﬀ erence 
0·16 (SE 0·11, mortality ratio 0·95, 95% CI 0·89 to 1·02, p=0·16), suggesting absolute risks of dying between ages 1·0 
and 6·0 years of roughly 2·5% albendazole versus 2·6% control. No speciﬁ c cause of death was signiﬁ cantly aﬀ ected. 
Interpretation Existing ICDS village staﬀ  can be organised to deliver simple pre-school interventions sustainably for 
many years at low cost, but regular deworming had little eﬀ ect on mortality in this lightly infected pre-school population.
Funding UK Medical Research Council, USAID, World Bank (albendazole donated by GlaxoSmithKline).
Introduction
Heavy worm infection can constrain physical develop-
ment.1,2 In areas where heavy infection is common, 
periodic deworming of school-age children can improve 
weight gain.3–5 Of three studies of urban pre-school 
children in Lucknow, north India, two suggested little 
eﬀ ect of deworming on growth and one showed a 
substantial eﬀ ect, perhaps large enough to reduce 
mortality signiﬁ cantly in a much larger study.6–9 The 
Integrated Child Development Service (ICDS) in Uttar 
Pradesh oﬀ ered an opportunity to test the eﬀ ects of 
deworming in children in rural areas. 
The ICDS has staﬀ ed child-care centres serving all 
children up to age 6 years in one-third of the villages in 
Uttar Pradesh. These centres can deliver simple health 
interventions, as long as all the villages in the same 
administrative area are asked to give the same 
intervention.10,11 We therefore planned a large cluster-
randomised trial of whether the ICDS could inexpensively 
and sustainably deliver anthelmintics at operational scale 
to rural pre-school children in Uttar Pradesh. The 
primary aim of the trial was to assess eﬀ ects of a widely 
practicable periodic deworming regimen on mortality at 
ages 1·0–6·0 years.12 
Plans for this deworming trial were eventually revised 
into plans for a factorial trial of albendazole, vitamin A 
(retinol), both, or neither that would assess the eﬀ ects of 
each agent on child mortality. This report focuses on the 
albendazole results; an accompanying report gives the 
vitamin A results.13
Methods
Study design 
This cluster-randomised study spanned seven adjacent 
districts (area 35 000 km², 3 degrees of latitude by 1 of 
longitude; ﬁ gure 1). Excluding major municipalities, they 
consist of 118 largely rural administrative blocks (units that 
generally have a rural population of more than 100 000). 
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72 of these blocks could participate; 36 were cluster-
randomly allocated albendazole every 6 months for 5 years 
and 36 open control (ﬁ gure 2). 
The study was based in Lucknow, the Uttar Pradesh 
state capital. The 72 participating blocks were those 
within a few hours drive that the ICDS director in 
Lucknow judged in 1998 to have a reasonably well 
functioning ICDS system with willing district and block 
ICDS directors and paid workers in most village 
anganwadi child-care centres (AWCs; anganwadi means 
courtyard). A typical rural AWC serves a village population 
of 1000 (10–15% aged 1–6·0 years); large villages can have 
more AWCs. The AWC workers, usually local women 
(plus assistants), give pre-school education, give 
nutritional supplements to malnourished children, and 
record births and pre-school deaths. AWCs register about 
two-thirds of under-5s (and one-third of 5-year-olds) for 
possible nutritional supplementation, although levels of 
AWC attendance and supplementary nutrition in Uttar 
Pradesh are often low.10 AWC workers can help health 
workers to organise immunisation and pre-school health 
services. In one block, a court order closed down all 
AWCs, but treatment and follow-up continued via the 
local administration (known as the panchayat). 
In these 72 blocks, 8511 AWCs were deemed functional 
in 1998 (or, in a few cases, were expected to become 
functional during the study), and 8338 (98%) of these 
remained functional for most or all of the study and so 
were included (ﬁ gure 2). At any one time the study 
population for assessment of mortality was all pre-school 
children then aged 1·0–6·0 years in the deﬁ ned 
catchment areas of these 8338 AWCs. Reported age was 
often rounded up or down to approximate whole 
numbers of years. 
In a typical block these study catchment areas included 
10 000–20 000 children aged 1·0–6·0 years, so at any one 
time the study included 1 million such children. During 
the study another million 1-year-olds joined as the 6-year-
olds left, so at one time or another the study included 
about 2 million children. The study continued for 5 years, 
and recorded 25 000 child deaths during 5 million child-
years of follow-up. The study was approved by King 
George’s Medical University ethics committee (Lucknow, 
India) and by the ICDS directors, but no permissions 
were obtained from the population, except when faecal 
samples were sought.
Randomisation and masking
Neighbouring blocks (clusters), in groups of four, were 
randomly allocated in Oxford, UK, using a factorial 
design to: (1) usual care; (2) 6-monthly vitamin A; 
(3) 6-monthly albendazole; or (4) both. No placebos were 
used; the control was open. Randomisation was 
stratiﬁ ed in groups of four blocks, where possible in the 
same district. No other relevant details of the blocks 
were known at baseline. This report compares 
albendazole (36 blocks) versus not (36 blocks), largely 
ignoring retinol allocation and stratum. Sensitivity 
analyses showed the main ﬁ ndings were unchanged 
when adjusted for district.
Procedures 
GlaxoSmithKline donated albendazole in pots of 
150 chewable tablets (400 mg Zentel). Dose was 
independent of age. When treatment became due (in 
April or October), in each treatment-allocated block a 
mass-treatment day was selected on which all children of 
apparent age 6–72 months in all study AWCs in that 
block would be given the trial treatment by their AWC 
worker. The few children missed were often treated soon 
afterwards.
Implementation of the mass-treatment days was 
encouraged and monitored independently by project 
staﬀ  and state government staﬀ . At the previous monthly 
block meeting, each supervisor in the AWCs to be treated 
collected 150 tablets (plus extras, for large AWCs) and, on 
the selected day, administered treatment. Villagers were 
alerted beforehand. 
To ensure AWC workers undertook mass-treatment on 
the chosen day, they were trained before the study (with 
refresher training in 45 blocks), discussed matters at their 
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Figure 1: Location of the seven DEVTA study districts in the state of Uttar Pradesh in north India
1 Lucknow (study centre: Lucknow city), 2 Rae Bareli, 3 Unnao, 4 Kanpur, 5 Hardoi, 6 Lakhimpur, 7 Sitapur. Within 
the districts, the study areas were largely rural.
Articles
1480 www.thelancet.com   Vol 381   April 27, 2013
monthly block meetings before and afterwards, and knew 
that on all mass-treatment days unannounced visits were 
made to every fourth AWC on a numbered list for each 
block to check that distribution had started, followed by 
visits 1 week later to check numbers dispensed and 
interview focus groups about receiving treatment. 
During the third study year, study monitors abstracted 
from local records name, sex, age, and father’s name for 
all (just over 1 million) pre-school children in the study 
areas. There should have been little undercount of 
children, but numbers by month of age showed, as 
expected, substantial undercount of young infants, and 
ages were often approximate. After removal of apparently 
duplicated records (about 1% at ages 1·0–6·0 years), this 
mid-study census was used before each subsequent 
treatment day to list all in 25 AWCs per block with 
predicted age 12–70 months (ie, well within the range to 
be treated). Monitors established soon after whether the 
children listed had actually been treated (and whether 
they were currently registered with the AWC).
Annually, Oxford randomly selected one AWC per 
block for teams (one phlebotomist, two ﬁ eldworkers, one 
driver) to survey 1–5 months after a mass-treatment day 
30 pre-school children (six per year of age; if fewer were 
available, a neighbouring AWC was included), seeking 
from them blood and faecal samples. In practice, full 
information with complete assay results was obtained for 
about 24 children per block. Children surveyed were not 
randomly chosen, and tended to be selected by AWC 
workers from those registered with the AWC. Villagers 
decided after public discussion whether the village would 
cooperate; if it did, no caregiver then chose to refuse 
consent. Only one selected village refused; an adjacent 
village replaced it. 
After marking consent, caregivers were asked whether 
the previous mass-treatment had been received (and, if so, 
whether diarrhoea, vomiting, or fever had followed) and 
about recent (past 4 weeks) fast or diﬃ  cult breathing 
suggesting WHO-deﬁ ned pneumonia,14 diarrhoea 
(≥3 loose stools per day), measles, conjunctivitis, fever, and 
skin infection. Fieldwork teams were trained to measure 
height (to 1 mm; stadiometer), weight (to 0·1 kg; electronic 
scales, calibrated daily) and ﬁ nger-prick haemoglobin.15 
Blood and faecal samples were collected for central retinol 
assay16 and central formalin-ether-concentration helminth 
egg assay17 (useable only after mid-study, when egg-
counting methodology greatly improved).
Deaths were recorded by 18 full-time motorcycle 
village-to-village monitors. Monitors covered four 
neighbouring blocks at a time, one in each treatment 
group, and within 6 months visited all (about 500) study 
AWCs in those blocks to identify and visit households 
where in the past year a liveborn infant or child younger 
than 10 years had died, recording age, sex, name, parental 
names, and (by simple verbal autopsy) likely cause. 
Monitors were literate, but not medically trained 
(except by the study and experience during it). 
Identiﬁ cation of households where a death had occurred 
was from AWC workers, from their records, and from 
key informants (eg, village head, other village leaders, 
teacher, auxiliary nurse midwife). There was digit 
preference; ages were often rounded up or down, so we 
analyse deaths at age 1·0–6·0 years. Monitors knew 
supervisors would, with 5% probability, randomly re-
study selected villages shortly afterwards to ensure the 
relevant households had all been visited (and to help 
consolidate monitors’ discipline and methods). 
6 months later a diﬀ erent monitor visited the same 
blocks, again to record all deaths in the past year, so each 
death should have been reported twice, independently. 
Duplicates were eliminated manually, then by computer, 
in Lucknow, consulting monitors where necessary. The 
238 remaining duplicates at ages 1·0–6·0 years were 
eliminated in Oxford by computer matches (199 with the 
same AWC, sex, ﬁ rst three letters of father’s name, and 
date of death from a disease, 23 with matching for 
approximate date but closer other similarities, 16 with 
Of 118 administrative blocks in the seven DEVTA districts in north India,  
46 with many AWCs not functioning in 1998 were not included. 
72 blocks remained; parts of each of them became the study areas 
(ie, the catchment areas of the 8338 AWCs that were originally 
identiﬁed before random allocation as functional, and followed up*) 
Randomisation by block (balanced in groups of four neighbouring blocks) 
36 albendazole blocks (400 mg×11,
6-monthly, April 1999–April 2004), 
with 4246 AWCs functional
36 open control blocks (no
placebo tablets), with 
4265 AWCs functional
88 AWCs (2%) lost 
to follow-up*
85 AWCs (2%) lost
to follow-up*
36 albendazole blocks, with 4158 AWCs 
followed up
36 control blocks, with 
4180 AWCs followed up
11–14 6-monthly non-treatment visits scheduled to each AWC (ﬁrst before 
May, 1999, last after April, 2004) to record all deaths during this period
Total 100 654 visits to 8338 AWCs, with 97 231 infant deaths plus 
15 589 deaths at ages 1·0–2·9 years and 9993 at ages 3·0–6·0 years
NB Main treatment comparisons (based on cluster randomisation) compared 
72 block-speciﬁc average numbers of deaths per AWC
Figure 2: Flow diagram for the 72 mainly rural administrative blocks 
randomly allocated ﬁ ve years of six-monthly albendazole or open control 
AWC: anganwadi (ie, courtyard) child-care centre. In these 72 blocks, 
8338 child-care centres were followed up, with a total population at ages 
1·0–6·0 years of 1 million at any one time (hence 2 million ever in the study, 
May, 1999–April, 2004). *AWC catchment areas correspond approximately to 
villages; it was determined before randomisation which AWCs were then 
functional, and hence potential study areas; loss of an AWC to follow-up was 
deﬁ ned by having only 1–6 follow-up visits (mean only 3, as against 12 in 
included AWCs), and was generally because the AWC had ceased to function.
Articles
www.thelancet.com   Vol 381   April 27, 2013 1481
the same death reported in adjacent AWCs), leaving 
25 582 child deaths for analysis. During the third study 
year, monitors further undertook house-to-house surveys 
in every AWC to identify any missed deaths. 
Statistical analysis
Data were checked manually and (apart from our mid-
study census) double-entered; any obvious errors were 
corrected in the primary records. The FoxPro database 
was sent monthly to Oxford and extensively queried, 
leading to interactive corrections. Faecal egg counts, 
anthropometry, blood assays, and recent morbidity rates 
were standardised (by multiple regression) for age, sex 
(50% male) and 6-month season (50% May–October: 
height and weight were further standardised for study 
half-year). Age standardisation was to 3·0, 2·0, or 
4·0 years, respectively, for age ranges 1·0–6·0, 1·0–2·9, 
or 3·0–6·0 years. 
The prespeciﬁ ed primary analysis (see appendix of 
accompanying report13) was of pre-school child mortality, 
operationalised because of digit preference in stating 
ages as mortality at reported ages 1·0–6·0 years during 
the 5-year study period. This outcome was secondarily 
subdivided into ages 1·0–2·9 and 3·0–6·0 years, and 
into study years 1–2 and 3–5. Analyses of the eﬀ ects of 
albendazole allocation on any category of mortality (or on 
any other outcomes—eg, faecal egg counts, blood 
biochemistry, anthropometry, or morbidity) derived only 
from the 72 block averages for the outcome or explanatory 
factors of interest, giving all blocks equal weight (as they 
were of similar size). If albendazole did nothing, the 
mean of the 36 albendazole block averages would have 
been the mean of 36 selected randomly from these 
72 values. Equivalently, the 72 values were regressed on 
two yes/no indicator values for retinol and albendazole 
allocation and on any explanatory factors.
Mortality analyses ﬁ rst calculated for each block the 
mean number of child deaths recorded per study AWC 
and the mean number of infant deaths recorded per 
study AWC. Analyses of eﬀ ects on child mortality 
regressed child deaths per study AWC (72 values) on 
albendazole allocation (0/1), with simultaneous 
adjustment for retinol allocation (also 0/1), for an 
interaction term (±1, included only in simultaneous 
analyses of both treatments), and for infant deaths per 
AWC (an important explanatory factor that cannot have 
 Ages 1·0–2·9 years Ages 3·0–6·0 years Ages 1·0–6·0 years
Albendazole 
(n=783)
Control 
(n=802)
95% CI for 
diﬀ erence
Albendazole 
(n=1806)
Control 
(n=1774)
95% CI for 
diﬀ erence
Albendazole 
(n=2589)
Control 
(n=2576)
95% CI for 
diﬀ erence
Faecal worm eggs (% prevalence)
Ascaris 15·7%* 27·0% 6·7, 15·9 11·9%* 28·8% 14·7, 19·0 12·9%* 28·1% 13·4, 17·0
Hookworm 4·7%† 8·0% 1·0, 5·6 3·5%* 9·3% 4·2, 7·4 3·8%* 8·9% 3·9,  6·3
Either nematode 19·8%* 33·9% 9·5, 18·7 15·3%* 36·5% 18·9, 23·5 16·4%* 35·6% 17·2, 21·1
Tapeworm‡ 5·7% 4·9% –3·1, 1·3 4·2% 6·2% 0·5,  3·5 4·5%  5·7% –0·1,  2·4
Other biomedical measurements
Weight (kg) 9·45 9·41 –0·22, 0·15 12·72 12·68 –0·21, 0·14   11·09 11·05 –0·19, 0·09
Height (cm) 74·2 74·6 –0·2, 1·0 88·7 88·6 –0·8, 0·6  81·6 81·6 –0·6, 0·6
BMI (kg/m2) 17·2 16·9 –0·6, 0·1 16·1 16·1 –0·2, 0·2  16·6 16·5 –0·3, 0·1
Haemoglobin (g/L) 94·6 95·6 –1·0, 2·9 103·8 103·2 –2·2, 1·0  99·6 99·4 –1·5, 1·2
Illness in past 4 weeks (% prevalence)
Diarrhoea 40·6% 42·5% –5·1, 8·8 33·5% 33·2% –4·9, 4·3 37·6% 37·6% –4·2, 4·3
Cough 19·1% 18·4% –5·5, 4·1 18·0% 17·6% –3·7, 2·9 18·5% 18·0% –3·8, 2·8
Runny nose 15·2% 12·2% –8·3, 2·3 11·4% 10·6% –4·0, 2·4 12·6% 11·5% –4·2, 2·0
Fast breathing 4·3% 4·4% –2·4, 2·5 2·5% 3·9% 0·1, 2·7 3·1% 4·1% –0·3, 2·2
Diﬃ  cult breathing 4·1% 4·0% –2·3, 2·2 2·5% 3·3% –0·4, 2·1 3·1% 3·6% –0·6, 1·7
Noisy breathing 2·8% 2·9% –1·9, 2·1 2·2% 2·1% –1·1, 1·0 2·4% 2·5% –1·1, 1·1
Measles 1·9% 1·3% –1·8, 0·7 0·9% 1·0% –0·7, 1·1 1·3% 1·3% –0·9, 0·8
Fever 35·7% 33·7% –7·3, 3·4 28·5% 28·2% –4·3, 3·7 31·1% 30·6% –3·9, 2·8
Skin infection 15·1% 13·5% –5·6, 2·3 13·4% 14·1% –3·1, 4·5 14·1% 14·1% –3·4, 3·4
Conjunctivitis 1·8% 2·3% –1·0, 2·1  2·1% 2·2% –1·2, 1·4 2·0% 2·2% –0·9, 1·4
Biomedical visit to one random village per block per year: 5165 children with no data missing. *p<0·00001. †Two-sided p<0·01. ‡p=0·01 at ages 3·0–6·0 years only for 
tapeworm (but, tapeworm result is opposite at younger ages and is non-signiﬁ cant at all ages). Trichuris was not present. Each entry is the mean of 36 block-speciﬁ c values. 
CIs are for the eﬀ ects of choosing 36 out of the 72 such values. All results are standardised to ages 2·0, 4·0, or 3·0 years, respectively, for age groups 1·0–2·9, 3·0–6·0, 
or 1·0–6·0 years, and to 50:50 averages for half-year season and for sex. Height, weight, and body-mass index (BMI) are further standardised for study half-year. The 
sex-speciﬁ c diﬀ erences (not shown) do not diﬀ er materially from these sex-standardised diﬀ erences.
Table 1: Eﬀ ects of albendazole allocation on prevalence of worm infection, weight, height, haemoglobin, and recent ill health (generally as reported by 
the child's guardian) in a subsample from each of the 72 blocks during the second half of the study, by age 
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been materially aﬀ ected by trial treatment, and varied 
two-fold between blocks). Sensitivity analyses explored 
the relevance of not adjusting for infant mortality or 
of additional adjustment for district (by which 
randomisation had been stratiﬁ ed). All these analyses 
did not depend on the mid-study census, but further 
sensitivity analyses explored the eﬀ ect of adjustment for 
the census estimate of child population per AWC (an 
unimportant factor, since it varied little between blocks). 
72 blocks were made available for this study by the 
ICDS. On the assumption that the 72 block-speciﬁ c 
mortality rates observed in the study at ages 1·0–6·0 years 
would be about 2–3% with SD 0·5, the mean mortality 
reduction would have SE 0·12 (2SD/√72), so if treatment 
reduced mortality by 0·5% (ie, by about a ﬁ fth) the study 
would have a 95% chance of getting p<0·01. SAS 
version 9.1 was used. This trial is registered at 
ClinicalTrials.gov, NCT00222547.
Role of the funding source 
Study sponsors had no role in design, conduct, analysis, 
or interpretation. SA, RP, DB, and SR had full data access 
and entirely controlled submission for publication. 
Results 
Compliance with treatment allocation was good. 
Unannounced visits to a quarter of the AWCs in the 
albendazole blocks on or just after each mass-treatment 
day conﬁ rmed that 98% (10 364/10 597 visits) were 
distributing treatment. Independently, enquiries a week 
after mass-treatment days about lists of named children 
from the mid-study census conﬁ rmed treatment of 95% 
(131 631/138 333) of those registered with the AWC and 
73% (76 490/104 925) of those not. Because two-thirds of 
under-5s and one-third of 5-year-olds were AWC-
registered, overall compliance was about 86%. Consistent 
with this ﬁ nding, the biomedical surveys of randomly 
chosen AWCs, which tended to over-sample AWC-
registered children, found caregivers reporting 92% 
(2388/2589) had received albendazole on the previous 
mass-treatment day. AWC workers in albendazole and 
control blocks held non-study mebendazole to treat 
children with obvious worms; otherwise, there was little 
non-study anthelmintic treatment. Loss to follow-up was 
similarly uncommon in both groups (2% [88/4246] 
albendazole, 2% [85/4265] control; ﬁ gure 2), and was 
generally due to AWC closures.
Allocation to albendazole halved faecal worm egg 
prevalence 1–5 months after mass-treatment days. Faecal 
assays were available during the second half of the study 
for 5165 children with complete information on all assays 
and questionnaire replies, 2589 in albendazole-allocated 
versus 2576 in control blocks (table 1). Among them, the 
proportion with nematode (Ascaris or hookworm) eggs was 
16% in the albendazole-allocated blocks versus 36% in 
control blocks, but in both albendazole and control groups 
any infection was generally light (median eggs per g faeces, 
if non-zero, Ascaris 96 [IQR 69–127], hookworm 83 
[62–115]). The control prevalence matches previous 
estimates for north India.18,19 Trichuris eggs were not found. 
The proportion with tapeworm eggs (Hymenolepis spp) 
was, as expected, not signiﬁ cantly reduced. 
Albendazole remains almost wholly inside the 
intestine, and oral treatment was not signiﬁ cantly 
associated with any immediate adverse eﬀ ects. In 
36 albendazole-allocated blocks, 362 children died 
during the 7 days before mass-treatment was due and 
366 during the next 7 days. Caregivers were asked at the 
biomedical surveys whether the previous treatment had 
been closely followed by acute illness. No signiﬁ cant 
diﬀ erences in vomiting, diarrhoea, or fever were seen 
between retinol plus albendazole, retinol alone, and 
albendazole alone. Among 6290 children in 18 retinol-
and-albendazole blocks, vomiting was reported for 
29 children in ﬁ ve blocks, diarrhoea for ten children in 
two blocks, and fever for six children in three blocks; 
among 6686 children in 18 albendazole-only blocks, 
vomiting was reported for 15 children in six blocks, 
diarrhoea for 12 in three blocks, and fever for three 
children in one block; among 6433 children in 
18 retinol-only blocks, vomiting was reported for 
25 children in four blocks, diarrhoea for 14 children in 
two blocks, and fever for 37 children in two blocks (both 
with obvious outbreaks).
Ascaris eggs Hookworm eggs Either type of nematode egg
No eggs 
(n=1858)
Eggs 
(n=718)
Diﬀ erence (95% CI)* No eggs 
(n=2336)
Eggs 
(n=240)
Diﬀ erence (95% CI)* No eggs 
(n=1660)
Eggs 
(n=916)
Diﬀ erence (95% CI)*
Weight (kg) 11·07 11·02 0·05 (–0·08, 0·17) 11·06 11·02 0·04 (–0·15, 0·23) 11·08 11·01 0·07 (–0·04, 0·19)
Height (cm) 81·7 81·4 0·3 (–0·16, 0·76) 81·6 81·7 –0·1 (–0·84, 0·57) 81·7 81·4 0·3 (–0·11, 0·75)
BMI (kg/m²) 16·5 16·6 –0·1 (–0·20, 0·08) 16·5 16·4 0·1 (–0·13, 0·30) 16·5 16·5 0·0 (–0·17, 0·09)
Haemoglobin (g/L) 99·2 99·6 –0·4 (–1·42, 0·56) 99·3 99·0 0·4 (–1·17, 1·89) 99·2 99·4 –0·2 (–1·12, 0·74)
Biomedical visit to one random village per block per year (from mid-study): 2576 controls with no data missing. *Individual values for weight, height, body-mass index (BMI), and haemoglobin were 
standardised to age 3·0 years, 50% male, and 50% wet season (May–Oct), and then standardised for village (leaving the means unchanged). Hence, regressing the standardised individual values on the absence or 
presence of faecal eggs (0/1) eﬀ ectively compares children in one village who do have eggs with others in the same village who do not. 
Table 2: Associations within 116 of the 4180 control villages between faecal worm eggs (absent/present) and mean weight, height, and haemoglobin during the second half of the study 
(analyses of individuals) 
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Weight, height, and haemoglobin were not signiﬁ cantly 
improved by albendazole. After at least 2 years of 
treatment, mean weight at ages 3·0–6·0 years 
(standardised to age 4·0 years, half male, half female) in 
all surveyed children, infected or not, was 12·72 kg 
albendazole versus 12·68 kg control, diﬀ erence 0·04 kg 
(95% CI –0·14 to 0·21 kg, p=0·66; table 2). This null result 
is statistically compatible with albendazole increasing 
weight by 0·5 kg in children who are actually infected. 
When, however, children in the same control village were 
compared with each other, the presence of faecal eggs was 
not associated with any signiﬁ cant diﬀ erences in weight, 
height, or haemoglobin (table 2); the upper conﬁ dence 
limit for the weight diﬀ erence associated with an 
individual having nematode eggs was only 0·2 kg. 
Likewise, there were no eﬀ ects of allocation to albendazole 
on prevalence of ill health at the time of the visit (table 1). 
These null ﬁ ndings were independent of age and sex. 
During the entire study, after exclusion of duplicated 
records and stillbirths, monitors recorded 97 231 deaths 
in infancy (86 084 before age 6 months), 15 589 at ages 
1·0–2·9 years and 9993 at ages 3·0–6·0 years (ﬁ gure 2). 
These numbers include any extra deaths identiﬁ ed by the 
special mid-study retrospective enquiry (which found 
similar numbers of missed child deaths in the two 
treatment groups, suggesting little ascertainment bias). 
Combined with our mid-study census listing a million 
children, this ﬁ nding suggests at least 9% infant 
mortality and about 2·5% child mortality.
Figure 3 shows a 69% correlation between the numbers 
of infant and child deaths recorded per AWC. As any trial 
treatment in infancy began at 6–12 months of age and 
most infant deaths occur much earlier, overall infant 
mortality cannot have been materially aﬀ ected by 
treatment. Hence, this strong correlation reﬂ ects 
diﬀ erences not due to treatment between the numbers of 
infant deaths recorded per AWC. Conﬁ rming this 
conclusion, the correlation between infant and child 
mortality was equally strong among blocks that had all 
had the same treatment; ﬁ gure 3. We therefore used 
number of infant deaths as an explanatory factor to reduce 
chance variation in our main analyses of the eﬀ ects of 
treatment allocation on the number of child deaths.
Table 3 shows the ﬁ ndings for child mortality at ages 
1·0–2·9 years, 3·0–6·0 years, and 1·0–6·0 years, along 
with the relative risk for the age range 1·0–6·0 years. 
Overall child mortality was 5% lower in albendazole than 
in control blocks, but because randomisation was by block 
rather than by AWC or by individual this 5% diﬀ erence is 
not signiﬁ cant (risk ratio [RR] 0·95, CI 0·88–1·02, p=0·16).
Sensitivity analyses (table 3) showed this RR was little 
changed (although its CI was narrowed) by adjustment for 
infant deaths, and would be little changed by use of 
6-month mortality instead of infant mortality to correct for 
initial variation in prognosis, or by further adjustment for 
district or for mean number of children per AWC. There 
was no signiﬁ cant interaction between the eﬀ ects of retinol 
and albendazole (interaction p=0·83). So, RR was again 
little changed (although its CI was widened) by restricting 
attention to 18 albendazole-plus-retinol versus 18 retinol-
alone blocks, where monitoring could not be biased by one 
group getting no treatment. Table 3 also provides the 
separate results in all four (2×2) treatment groups.
The main contributor to the overall mortality diﬀ erence 
was diarrhoeal mortality, which was 9% lower with 
albendazole, but this 9% diﬀ erence was also not 
signiﬁ cant (RR 0·91, 95% CI 0·80–1·03). If the diﬀ erence 
in overall mortality was a chance ﬁ nding, the RR would 
be expected to be similar in various subgroups, and it 
was similar in the ﬁ rst 2 years and last 3 years (see 
accompanying report for illustration of the trial 
timelines13) and in boys and girls. There was an 80% 
correlation between male and female child mortality 
rates in diﬀ erent blocks. 
The annual number of deaths per AWC was greater at 
ages 1·0–2·9 than at 3·0–6·0 years (particularly for 
diarrhoea, pneumonia, and malnutrition), greater in 
girls than in boys, and greater in earlier than in later 
study years, but for no category of age, disease, or sex 
was there a signiﬁ cant eﬀ ect of albendazole on mor-
tality. Even for children who had been on treatment 
more than 2 years (ie, for mortality at ages 3·0–6·0 years 
during the last 3 study years) there was no signiﬁ cant 
diﬀ erence in mortality between blocks allocated 
albendazole and control. 
To convert numbers of deaths per AWC into risks, 
population estimates are needed. Our mid-study census 
enumerated about 119 children of age 1·0–6·0 years 
per AWC (65 male, 54 female). Because of strong digit 
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Figure 3: Correlation between 72 block-specific average numbers of 
infant and child deaths per child-care centre (AWC) during the entire 
study
The inter-block correlation (illustrated here) between numbers of infant and 
child deaths per AWC was 68·7% ignoring trial treatment allocation (or 68·4% 
given the four-way allocation to albendazole, retinol, both, or neither), and 
ranged from 66–71% within the four treatment groups. Mortality at ages 
0–6 months had correlation 99·3% with infant and 68·2% with child mortality.
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preferences in describing ages and possible undercount, 
particularly of young infants and children not registered 
with the AWC, this number is only approximate. Never-
theless, ignoring any uncertainties in enumeration, 
11·7 infant deaths (6·2 male, 5·5 female) and 119 chil-
dren per AWC suggests at least 9% infant mortality 
(11·7 / [11·7 + 119] plus some undercounted mortality in 
early infancy). Likewise, 3·1 child deaths per AWC 
(1·4 male, 1·6 female) suggests about 2·5% child 
mortality at ages 1·0–6·0 years (3·1/119). These infant 
and child mortality rates are consistent with published 
estimates for rural Uttar Pradesh.20,21
Discussion
Some but not all previous studies of periodic population 
deworming have suggested appreciable weight gain.1–3 
The stated aims of the present albendazole trial were to 
establish whether twice-yearly deworming would be 
practicable within existing ICDS structures and, if so, 
whether it would provide sustainable beneﬁ ts in terms of 
improved physical growth and (the primary outcome) 
survival of pre-school children.12 In terms of assessing 
eﬀ ects on weight gain, this trial (which weighed only a 
representative few thousand children in a few dozen 
clusters) is no better powered than several previous 
studies, but in terms of assessing eﬀ ects on survival it is 
unique (enumerating 25 000 child deaths).3,6–8,22,23 Because 
of digit preference in recording ages, the primary endpoint 
was operationalised as mortality at recorded ages 
1·0–6·0 years. This outcome was secondarily subdivided 
into 1·0–2·9 and 3·0–6·0 years, and into the ﬁ rst 2 and 
last 3 study years. A major subsidiary aim was to establish 
whether the ICDS system could provide a cost-eﬀ ective 
and sustainable delivery mechanism for this or other 
simple health interventions in pre-school children. 
The subsidiary aim was fully achieved; 86% compliance 
was maintained over 5 years (with 95% compliance 
among the many children who were registered with the 
AWC). Focus group discussions attributed this 
compliance to political support, sustained and predictable 
drug supply, minimum additional work for AWC staﬀ  
(who did not themselves have to report on compliance), 
helpful staﬀ  training meetings, and the knowledge that 
coverage might well be monitored. Excluding donated 
drug, the total cost was US$100 000 per year (US$0·10 
per child), but this expense was mostly for evaluating the 
intervention. This suggests that, in villages with 
functioning ICDS anganwadi centres, delivery costs for 
simple pre-school interventions could be as low as for 
school-based health interventions.1,24,25
Number of child deaths recorded per AWC during the whole study, albendazole versus control (A vs C) 
and 95% CI for the diﬀ erence (C–A)*
Mortality rate ratio 
(RR=A/C), 
age 1·0–6·0 years
Absolute risk of 
death from age
1·0–6·0 years (%)
Age 1·0–2·9 years Age 3·0–6·0 years Age 1·0–6·0 years RR 95% CI Alben-
dazole
Control
A C CI for (C–A) A C CI for (C–A) A C CI for (C–A)
Cause of death
Diarrhoea 0·54 0·56 –0·04, 0·09 0·28 0·34 0·00, 0·11 0·82 0·90 –0·03, 0·19 0·91 0·80, 1·03 0·69% 0·76%
Pneumonia 0·33 0·32 –0·06, 0·03 0·12 0·12 –0·03, 0·02 0·45 0·44 –0·08, 0·05 1·03 0·89, 1·19 0·38% 0·37%
Measles 0·11 0·12 –0·02, 0·04 0·10 0·08 –0·04, 0·01 0·20 0·20 –0·06, 0·05 1·03 0·78, 1·35 0·17% 0·17%
Other infection/unknown 0·58 0·60 –0·07, 0·10 0·42 0·46 –0·02, 0·10 1·00 1·06 –0·08, 0·19 0·95 0·83, 1·08 0·84% 0·89%
Malnutrition 0·18 0·19 –0·03, 0·05 0·05 0·06 0·00, 0·03 0·23 0·25 –0·03, 0·08 0·91 0·73, 1·14 0·19% 0·21%
Other or external 0·11 0·11 –0·02, 0·03 0·18   0·20     –0·02, 0·05 0·29   0·31     –0·03, 0·07 0·94      0·80, 1·10 0·25% 0·26%
All causes, by subgroup
Boys 0·84 0·86 –0·05, 0·10 0·56 0·62 –0·01, 0·14 1·39   1·48 –0·03, 0·21 0·94      0·86, 1·02 2·14% 2·28%
Girls 1·01 1·04 –0·06, 0·12 0·59 0·63 –0·02, 0·10 1·61 1·68 –0·05, 0·19 0·96 0·89, 1·03 2·97% 3·10%
May, 1999–April, 2001 (2 years) 0·85 0·86 –0·07, 0·09 0·54 0·60 0·00, 0·12 1·39   1·46 –0·04, 0·19 0·95 0·88, 1·03 2·91%     3·07%
May, 2001–April, 2004 (3 years) 1·00 1·04 –0·06, 0·15 0·61 0·65 –0·05, 0·13 1·61 1·70 –0·09, 0·26 0·95 0·85, 1·05 2·26% 2·38%
Trial retinol 1·77 1·92 –0·05, 0·35 1·15   1·18 –0·14, 0·20 2·92 3·10 –0·13, 0·50 0·94 0·85, 1·04† 2·45% 2·60%
No trial retinol 1·93 1·89 –0·24, 0·16 1·15   1·32 0·01, 0·34 3·08 3·21 –0·18, 0·45 0·96 0·87, 1·06† 2·59% 2·70%
All causes, total‡ 1·85 1·91 –0·08, 0·20 1·15 1·25 –0·02, 0·22 3·00 3·16 –0·06, 0·38 0·95 0·88, 1·02§ 2·52% 2·65%
*Reduction (C–A) in number of child deaths per AWC and its standard error, s, were calculated by regression of 72 block-speciﬁ c numbers of child deaths per AWC on albendazole allocation (0/1), vitamin A 
allocation (also 0/1), and on the block-speciﬁ c numbers of infant deaths per AWC (to help correct for any pre-existing variation in prognosis. RR is then A/C with 95% CI (A – x)/(C + x) to (A + x)/(C – x), where 
x = 1·96s/2. Assuming approximately 119 (65 male, 54 female) children per AWC at ages 1·0–6·0 years, approximate absolute 5-year risks were calculated as ﬁ ve times (annual deaths per AWC)/(119, 65, or 54, as 
appropriate). Sensitivity analyses: further inclusion of district (as six indicators) or child population per AWC (which varied little) had no material eﬀ ect. †Interaction p=0·83. ‡6-month mortality had correlation 
99·3% with infant mortality and 68·2% with child mortality, so results were unchanged if it was used instead of infant mortality to correct for initial variation in prognosis; without either correction, numbers of 
child deaths per AWC at ages 1·0–2·9, 3·0–6·0, and 1·0–6·0 years would have been, respectively, 1·80 versus 1·96 (p=0·11), 1·13 versus 1·27 (p=0·031), and 2·92 versus 3·23 (p=0·045); RR=0·90 (0·82–1·00); 
absolute risks 2·46% versus 2·72%. §Two–sided p=0·16.
Table 3:  Eﬀ ects of albendazole allocation on pre-school child mortality:  absolute numbers of deaths per anganwadi child-care centre (AWC) by allocated treatment, albendazole versus 
control (A vs C), and, from these, mortality rate ratio (A/C) and approximate absolute risk of death from age 1·0 to 6·0 years
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For the primary aim, however, despite good compliance 
for 5 years and despite halving the prevalence of worm 
infection, the randomised comparison did not provide 
signiﬁ cant evidence of an eﬀ ect of deworming on 
survival (mortality RR 0·95, 95% CI 0·89–1·02). 
Although the conﬁ dence interval does not exclude a 
mortality reduction of about 10%, such an eﬀ ect is 
unlikely since there was no signiﬁ cant increase in 
weight gain—the proxy for better nutrition, our 
postulated mechanism for mortality reduction. 
The absence of a signiﬁ cant increase in weight is 
consistent with two previous studies of deworming this 
age group in north India,6,7 but discrepant with a third.8 
These three previous studies were in urban areas in 
which the prevalence of Ascaris eggs among controls 
would have been about twice as great as in the present 
study.6 The upper conﬁ dence limit for the average weight 
gain in the second half of the present study was 0·2 kg, 
much less than the lower conﬁ dence limit of 0·7 kg for 
the 2-year gain in the third study.8 The weight for age of 
the children in these two studies was similar, suggesting 
similar nutritional status, and we led both trials and are 
conﬁ dent of the reliability of each. This substantial 
discrepancy between the apparent eﬀ ects on weight gain 
in the two studies remains unexplained. 
Previous studies of population mortality from soil-
transmitted helminths have involved estimates of mortality 
from communities or hospital populations in unusual 
circumstances and oﬀ er little guidance as to the direct and 
indirect eﬀ ects in large general populations.26–29 Although 
further studies of the indirect eﬀ ects on mortality in much 
more intensely infected or worse nourished populations 
could well be worthwhile, reductions in mortality might be 
diﬃ  cult to demonstrate because of the age distribution of 
infection; for example, although the intensity of infection 
might be much greater in older child populations, they 
have lower overall mortality rates.1 
Overall, the present study shows that in this lightly 
infected rural population routine deworming of pre-
school children had little eﬀ ect on mortality (panel). This 
ﬁ nding does not rule out eﬀ ects on mortality in other 
populations, but any such eﬀ ects are generally likely to 
be small, so reduction in population mortality is unlikely 
to be a primary aim of deworming programmes.30
Panel: Research in context
The recently updated Cochrane Review3 of previous trials 
showed that intermittent deworming of school-age children 
can improve weight gain in some high-prevalence areas. No 
previous trial was large enough to assess eﬀ ects on mortality.
The present study shows that in a lightly infected rural Indian 
population routine deworming of pre-school children had little 
eﬀ ect on weight gain or on mortality. This ﬁ nding does not rule 
out eﬀ ects of deworming on mortality in other populations, 
although any such eﬀ ects are generally likely to be small.
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